ERBB2 and breast carcinoma: Yu et al. showed that a preparation of a tri-functional aptamer-siRNA chimera, with two, terminal aptamers targeting human epidermal growth factor receptor 2 (HER2) and 3 (HER3) and siRNA targeting EGFR mRNA in HER2+ breast cancer cells can specifically and efficiently inhibit breast cancer growth in a mice model system.